In summary, PD-1 ligands are upregulated via tumor-intrinsic mechanisms (i.e., 9p.24 copy gains, EBV mediated LMP1) on RSCs and tumor-extrinsic signaling to TAMs (i.e., interferons) in cHL to create a tolerogenic immune microenvironment. Here, PDCD1 is linked to neoplasm.